Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.

Literature DB >> 23835704

Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.

Brent W Weston¹, Melissa A Hayden, Kathryn G Roberts, Susan Bowyer, Johann Hsu, George Fedoriw, Kathleen W Rao, Charles G Mullighan.

Abstract

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2013 PMID： 23835704 DOI： 10.1200/JCO.2012.47.6770

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

Keyword Cloud
Cited

× No keyword cloud information.

85 in total

1. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.

Authors: Shalini C Reshmi; Richard C Harvey; Kathryn G Roberts; Eileen Stonerock; Amy Smith; Heather Jenkins; I-Ming Chen; Marc Valentine; Yu Liu; Yongjin Li; Ying Shao; John Easton; Debbie Payne-Turner; Zhaohui Gu; Thai Hoa Tran; Jonathan V Nguyen; Meenakshi Devidas; Yunfeng Dai; Nyla A Heerema; Andrew J Carroll; Elizabeth A Raetz; Michael J Borowitz; Brent L Wood; Anne L Angiolillo; Michael J Burke; Wanda L Salzer; Patrick A Zweidler-McKay; Karen R Rabin; William L Carroll; Jinghui Zhang; Mignon L Loh; Charles G Mullighan; Cheryl L Willman; Julie M Gastier-Foster; Stephen P Hunger
Journal: Blood Date: 2017-04-13 Impact factor: 22.113

2. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.

Authors: Etienne Lengline; Kheïra Beldjord; Hervé Dombret; Jean Soulier; Nicolas Boissel; Emmanuelle Clappier
Journal: Haematologica Date: 2013-11 Impact factor: 9.941

3. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.

Authors: Shannon L Maude; Sibasish Dolai; Cristina Delgado-Martin; Tiffaney Vincent; Alissa Robbins; Arthavan Selvanathan; Theresa Ryan; Junior Hall; Andrew C Wood; Sarah K Tasian; Stephen P Hunger; Mignon L Loh; Charles G Mullighan; Brent L Wood; Michelle L Hermiston; Stephan A Grupp; Richard B Lock; David T Teachey
Journal: Blood Date: 2015-02-02 Impact factor: 22.113

Review 4. Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.

Authors: Ching-Hon Pui
Journal: Front Med Date: 2014-12-15 Impact factor: 4.592

5. BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures.

Authors: Judith M Boer; João R M Marchante; William E Evans; Martin A Horstmann; Gabriele Escherich; Rob Pieters; Monique L Den Boer
Journal: Haematologica Date: 2015-06-04 Impact factor: 9.941

Review 6. Biology of childhood acute lymphoblastic leukemia.

Authors: Deepa Bhojwani; Jun J Yang; Ching-Hon Pui
Journal: Pediatr Clin North Am Date: 2015-02 Impact factor: 3.278

7. Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.

Authors: Judith M Boer; Jasper E Koenders; Bronno van der Holt; Carla Exalto; Mathijs A Sanders; Jan J Cornelissen; Peter J M Valk; Monique L den Boer; Anita W Rijneveld
Journal: Haematologica Date: 2015-03-13 Impact factor: 9.941